Results show 83% sensitivity and 89% specificity in predicting whether small molecule drugs will cause clinical seizures CNS-3D Brain Organoids are 13x more predictive than animal models Data from 120 ...

Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain ...

LONDON--(BUSINESS WIRE)--Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules ...

The International Society for CNS Drug Development (ISCDD), a non-profit organization dedicated to advancing central nervous system drug development, is pleased to announce that Suresh Durgam, MD, has ...

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal ...

Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights ...

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology ...

Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and ...

LAS VEGAS, March 6, 2026 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD), a non-profit organization dedicated to advancing central nervous system drug development, is ...